Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine



Rating:

Share or cite this content

Citations should be made in the following way:
Thierry Berghmans (Belgium), Luis Paz-Ares (Spain). Predictive biomarker of immune checkpoint inhibitors efficacy. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Member's Comments

No comment yet.

Related content which might interest you: The efficacy of immune checkpoint inhibitors in thoracic malignancies Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020 Year: 2021 Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019 The clinical benefits of immune checkpoint inhibitors for thymic carcinomas Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies? Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis Source: Eur Respir J, 55 (6) 2000038; 10.1183/13993003.00038-2020 Year: 2020 Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study Source: ERJ Open Res, 6 (1) 00165-2019; 10.1183/23120541.00165-2019 Year: 2020 Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Role of altered immune response in CF and implication for antiinflammatory therapies Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012 Role of pharmacogenomics in host response to treatment Source: Annual Congress 2004 - PG7 - Application of genomics and proteomics to pulmonary disease Year: 2004 Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Immunotherapy improves inflammatory response and lymphocyte apoptosis as a new therapeutic target in sepsis rat Source: Annual Congress 2009 - Severe sepsis and multiple organ failure Year: 2009 Use of immune cell function assay in immune surveillance of lung transplant recipients: Correlations with clinical outcome and other immune assays Source: Annual Congress 2012 - Optimising outcomes after lung transplantation Year: 2012